Deals, Diagnostics, Partnering

Collaborative R&D for prostate cancer prognostic test

Posted on 25 November 2013

Tags: ,

Definiens and Metamark Genetics announced a multi-year agreement covering use of the Definiens image analysis solution for the ProMark.

ProMark is a multiplex immunofluorescence test that integrates Definiens’ core image analysis platform, Cognition Network Technology.

It is to automatically classify prostate tumor “regions of interest” and quantify novel proteomic markers expressed in prostate biopsies.

Definiens’ software platform will be used to support Metamark’s fully automated analysis of clinical prostate cancer biopsies.

Related

Report: Diagnostics Partnering Terms and Agreements 

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply